Comparative Study on the Efficacy and Safety of Microwave Ablation and Lobectomy in the Treatment of Ground Glass Nodules Located in the Pulmonary Hilar Region
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 100
- 主要终点
- 3-year recurrence-free survival rate
研究概览
简要总结
GGO is a characteristic focus of early lung cancer. Due to the abundant peripheral blood vessels and bronchial tissues around the GGO lesions located in pulmonary hilar, only lobectomy could be used for the surgical treat of hilar GGO lesions which will make the significantly decline of the pulmonary function after surgery and affect the quality of life to a great extent. Our previous study has reported a new blunt-tip MWA electrode (MTC-3CA-II3, Vison Medical Inc.) for the treatment of GGO lesions. The blunt-tip MWA electrode could improve the safety of GGO ablation, significantly reduce the occurrence of bleeding and hemoptysis, which made it possible to ablate GGO in the hilar region safely. In this study, the blunt-tip MWA electrode was used in the treatment of patients with hilar GGO lesions, and the efficacy and safety of microwave ablation and lobectomy in the treatment of ground glass nodules located in the pulmonary hilar region were evaluated and compared.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The age ranged from 18 to 75 years old, male or female;
- •GGO lesions in the hilar region were diagnosed by imaging examination (CT / PET-CT). During the follow-up of 6-12 months, the lesions increased by more than 2mm, the solid components increased, or there were obvious solid components, or the GGOs were judged to be highly malignant by imaging.
- •The size of GGO lesions was 8mm-3cm, and the number of nodules was ≤
- •There was no lymph node metastasis, intrapulmonary metastasis or distant organ metastasis;
- •After multidisciplinary evaluation, the patients were feasible for lobectomy and CT guided microwave treatment;
- •No bleeding tendency, normal coagulation function or coagulation dysfunction can be corrected after treatment;
- •Patients and /or family members agreed to join the clinical trial and signed informed consent.
排除标准
- •The general condition of the patient is very poor, ECOG physical fitness score > 2, unable to tolerate lobectomy and MWA treatment, or has relevant contraindications;
- •The lesions had received other treatments before; patients with regional lymph node metastasis or distant metastasis or with pleural fluid and ascites;
- •Patients with poor compliance;
- •Severe heart, lung, kidney, brain and other important organ diseases;
- •The researcher believes that it is not suitable for inclusion
结局指标
主要结局
3-year recurrence-free survival rate
时间窗: 3 year after treatment
3-year recurrence-free survival rate
次要结局
- Postoperative hospital stay(During hospitalization)
- Total hospitalization expenses Total hospitalization expenses(During hospitalization)
- Incidence of complications(Within 1 month after operation)
研究者
Chi Jiachang
Deputy Chief Physician
RenJi Hospital